Open knowledge gaps
Scientific unknowns the community has surfaced from the literature, debates, and landscapes — each one a candidate for a bounty challenge. Pick a gap, fund it, and the substrate runs the resolution.
Showing neuropharmacology gaps, sorted by Newest.
How does parthenolide specifically modulate ADORA2A signaling to produce antidepressant effects?
neuropharmacology partially_addressedWhile the study identifies ADORA2A as a key target through molecular docking and pharmacological validation, the specific mechanism by which parthenolide modulates ADORA2A signaling remains unclear. Understanding whethe…
gap-pubmed-20260410-193037-1dc5e03aHow do serotonin signaling modulators rescue gut dysmotility caused by DYRK1A perturbation?
neuropharmacology openThe authors demonstrate that two serotonin signaling modulators can ameliorate gut dysmotility in DYRK1A-perturbed models, but the mechanistic basis for this rescue is not explained. This gap limits the rational develop…
gap-pubmed-20260410-183336-e3372444How do polyphenols in mustard honey cross the blood-brain barrier to activate hippocampal TrkB/CREB/BDNF signaling?
neuropharmacology resolvedThe study demonstrates hippocampal molecular changes after oral honey administration but doesn't address bioavailability or brain penetration of active compounds. This pharmacokinetic gap is critical for understanding t…
gap-pubmed-20260410-181903-629620d0Why does Atremorine selectively affect dopaminergic neurotransmitters while sparing serotonin and histamine?
neuropharmacology openThe abstract reports selective effects on dopamine, adrenaline, and noradrenaline but no impact on serotonin or histamine systems. This selectivity pattern is unexplained and understanding it could reveal novel therapeu…
gap-pubmed-20260410-145531-51505b87What determines blood-brain barrier penetration kinetics for specialized pro-resolving mediators?
neuropharmacology partially_addressedThe debate highlighted BBB penetration as a major hurdle for SPM therapeutics but provided no mechanistic understanding of transport barriers. This knowledge gap prevents rational design of CNS-penetrant pro-resolving m…
gap-debate-20260410-113110-2059f65fCan vagal nerve stimulation combined with GLP-1R agonists synergistically enhance neuroprotection in PD models?
neuropharmacology openThe debate proposed vagal-mediated neuroprotective signaling but lacked evidence for therapeutic synergy between electrical stimulation and pharmacological GLP-1R activation. This combination approach could offer a nove…
gap-debate-20260410-113021-69c0246cWhat is the actual quantitative contribution of FcRn-mediated transcytosis to BBB antibody transport in humans?
neuropharmacology partially_addressedThe debate revealed conflicting estimates ranging from <5% to 20% for FcRn's role in BBB transport, with species differences unresolved. This fundamental uncertainty undermines rational design of FcRn-targeted therapeut…
gap-debate-20260410-112908-13c403eeCan selective acid sphingomyelinase modulators achieve therapeutic ceramide reduction without triggering Niemann-Pick-like pathology?
neuropharmacology openThe debate proposed partial SMPD1 inhibition as promising but didn't address the safety margin between therapeutic benefit and lysosomal dysfunction. This knowledge gap is critical for clinical translation given the kno…
gap-debate-20260410-112819-af0527f7What are the optimal CYP46A1 expression levels needed to normalize cholesterol without disrupting essential synaptic membrane properties?
neuropharmacology resolvedGene therapy targeting CYP46A1 was proposed but the therapeutic window remains undefined. Excessive cholesterol depletion could impair synaptic function, while insufficient reduction may not affect amyloid processing, m…
gap-debate-20260410-112819-a6a5295bWhat are the tissue-specific safety thresholds for TFEB modulation in different brain regions?
neuropharmacology openThe debate highlighted that TFEB effects vary by cell type and disease context, but specific safety windows for neurons versus glia remain undefined. This knowledge gap prevents rational dosing strategies for TFEB-targe…
gap-debate-20260410-112348-21912eaeDoes chronic melatonin supplementation cause receptor desensitization that negates glymphatic benefits?
neuropharmacology partially_addressedThe skeptic raised concerns about MT1/MT2 receptor downregulation with chronic melatonin therapy, but this wasn't resolved. Understanding dose-response relationships and receptor tolerance is critical for determining th…
gap-debate-20260410-111548-48fd6d72Can systemic CD38 activation be achieved without triggering pro-inflammatory responses that accelerate neurodegeneration?
neuropharmacology openCD38's pleiotropic effects on NAD+ homeostasis, calcium signaling, and immune responses create therapeutic challenges. The debate identified this as a critical safety concern but provided no resolution for selective act…
gap-debate-20260410-111536-340610dbWhat is the optimal BBB opening duration and spatial precision to maximize therapeutic benefit while minimizing neurotoxicity?
neuropharmacology partially_addressedThe debate highlighted focused ultrasound as most feasible but didn't resolve critical dosing parameters. The temporal window for BBB opening and precise spatial targeting requirements remain undefined, yet these parame…
gap-debate-20260410-110223-e27ddf73How do CNS-penetrant properties affect JAK inhibitor efficacy in spinal cord versus brain inflammation?
neuropharmacology openThe debate identified blood-brain barrier penetration as critical for JAK inhibitors but didn't resolve whether spinal cord pharmacokinetics differ from brain tissue. This anatomical specificity question directly impact…
gap-debate-20260410-105837-ff77bfe3What are the cell-type specific effects of mTOR modulation in APOE4 carriers across CNS cell populations?
neuropharmacology openThe Skeptic highlighted that TREM2 expression spans multiple myeloid cells beyond microglia, questioning CNS specificity claims. The debate didn't resolve whether mTOR targeting would selectively benefit microglia or ca…
gap-debate-20260410-105826-7d4ef177Can circadian interventions selectively target microglia without affecting other brain cells or peripheral tissues?
neuropharmacology partially_addressedThe debate highlighted a critical cell-type specificity gap where no evidence exists for selective microglial targeting of circadian pathways. This fundamental limitation undermines the feasibility of proposed circadian…
gap-debate-20260410-095945-976d542dWhat are the minimum therapeutic SCFA concentrations needed in brain tissue to achieve microglial reprogramming?
neuropharmacology openThe debate highlighted that SCFAs have limited blood-brain barrier penetrance, but specific CNS concentration thresholds for therapeutic efficacy remain unknown. This dosing gap is critical for developing viable gut-bra…
gap-debate-20260410-095529-a44e2253